Piramal Imaging to Present Data at Annual Alzheimer’s Association International Conference

Piramal Imaging to Present Data at Annual Alzheimer’s Association International Conference
Piramal Imaging recently announced that it will present nine studies on the effects of Neuraceq (florbetaben F18 injection) at the Alzheimer's Association International Annual Conference (AAIC), July 18-23, 2015 at the Walter E. Washington Convention Center in Washington, D.C. Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. Data from these studies add to the current evidence on the clinical utility of identifying beta-amyloid (Ab) plaques in the brain. "The AAIC annual meeting is a unique gathering of researchers, physicians, advocates, patients and caregivers, all of whom are here to share information and learn about the latest research advances in the fight to improve the diagnosis and management of Alzheimer's disease," said in a recent press release Andrew Stephens, M.D., Chief Medical Officer of Piramal Imaging. "Piramal researchers are proud to be among the many esteemed scientists who are striving to improve the way physicians diagnose and manage this increasingly prevalent and devastating disease." On Wednesday 22nd of J
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *